会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Polymeric tissue sealant
    • 聚合物组织密封剂
    • US08961947B2
    • 2015-02-24
    • US12102157
    • 2008-04-14
    • Annemie RehorSimona Cerritelli
    • Annemie RehorSimona Cerritelli
    • A61K31/74A61L31/06A61L24/04C08G65/332C08G65/333C08G65/334C08L71/02
    • A61L24/046A61K47/34A61L24/0042A61L31/06A61L2400/04C08G63/00C08G65/3322C08G65/33306C08G65/3342C08G2650/58C08L71/02C08L2666/22
    • Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein: i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2 ii) the second precursor molecule is of the general formula: A-[(C3H6O)n—(C2H4O)m—B]i wherein m and n are integers from 1 to 200 i is greater than 2 A is a branch point B is a conjugated unsaturated group The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.
    • 用于制备用作组织密封剂的生物材料的方法,包含用于形成生物材料的前体的试剂盒以及所得生物材料在本文中描述。 生物材料由包含至少第一和第二前体分子的组合物形成,其中:i)第一前体分子是具有选自硫醇或氨基的x个亲核基团的聚(乙二醇)基聚合物, 其中x大于或等于2 ii)第二前体分子具有以下通式:A - [(C 3 H 6 O)n - (C 2 H 4 O)m -B] i,其中m和n是1至200i的整数更大 优于2 A是分支点B是共轭不饱和基团根据生物材料的所需性质选择前体。 任选地,生物材料含有添加剂,例如触变剂,不透射线剂或生物活性剂。 在优选的实施方案中,生物材料用于减少,抑制或含有患者体内的生物流体或气体的损失。
    • 2. 发明申请
    • POLYMERIC TISSUE SEALANT
    • 聚合组织密封剂
    • US20080253987A1
    • 2008-10-16
    • US12102157
    • 2008-04-14
    • Annemie RehorSimona Cerritelli
    • Annemie RehorSimona Cerritelli
    • A61K31/765C08L71/00A61P41/00
    • A61L24/046A61K47/34A61L24/0042A61L31/06A61L2400/04C08G63/00C08G65/3322C08G65/33306C08G65/3342C08G2650/58C08L71/02C08L2666/22
    • Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein: i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2 ii) the second precursor molecule is of the general formula: A-[(C3H6O)n—(C2H4O)m—B]i wherein m and n are integers from 1 to 200 i is greater than 2 A is a branch point B is a conjugated unsaturated group The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.
    • 用于制备用作组织密封剂的生物材料的方法,包含用于形成生物材料的前体的试剂盒以及所得生物材料在本文中描述。 生物材料由包含至少第一和第二前体分子的组合物形成,其中:i)第一前体分子是具有选自硫醇或氨基的x个亲核基团的聚(乙二醇)基聚合物, 其中x大于或等于2 ii)第二前体分子具有以下通式:<?in-line-formula description =“In-line formula”end =“lead”?> A - [(C
    • 3. 发明申请
    • COMPOSITIONS FOR TISSUE AUGMENTATION
    • 组织补充组合物
    • US20100034769A1
    • 2010-02-11
    • US12500843
    • 2009-07-10
    • Aaldert Rens MolenbergEnrico ZamparoLaurent RapillardSimona Cerritelli
    • Aaldert Rens MolenbergEnrico ZamparoLaurent RapillardSimona Cerritelli
    • A61K31/74
    • A61L27/26A61L2400/06A61L2430/38
    • Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).
    • 制备用于增加软组织和硬组织的生物材料的方法,包含用于形成生物材料的前体的试剂盒以及所得的生物材料在本文中描述。 生物材料由至少第一和第二前体成分形成。 第一前体组分含有至少两个亲核基团,第二前体组分含有至少两个亲电子基团。 第一和第二前体组分的亲核基团和亲电基团在生理温度下彼此形成共价键。 基于生物材料的所需性质选择前体。 在优选的实施方案中,第一前体是硅氧烷。 任选地,生物材料含有添加剂,例如触变剂,不透射线剂或生物活性剂。 在优选实施例中,生物材料用于增加脊柱的至少一个椎骨(椎体成形术)。
    • 4. 发明授权
    • Compositions for tissue augmentation
    • 用于组织增强的组合物
    • US08282912B2
    • 2012-10-09
    • US12500843
    • 2009-07-10
    • Aaldert Rens MolenbergEnrico ZamparoLaurent RapillardSimona Cerritelli
    • Aaldert Rens MolenbergEnrico ZamparoLaurent RapillardSimona Cerritelli
    • A61K31/74A61F13/00A61F2/00
    • A61L27/26A61L2400/06A61L2430/38
    • Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).
    • 制备用于增加软组织和硬组织的生物材料的方法,包含用于形成生物材料的前体的试剂盒以及所得的生物材料在本文中描述。 生物材料由至少第一和第二前体成分形成。 第一前体组分含有至少两个亲核基团,第二前体组分含有至少两个亲电子基团。 第一和第二前体组分的亲核基团和亲电基团在生理温度下彼此形成共价键。 基于生物材料的所需性质选择前体。 在优选的实施方案中,第一前体是硅氧烷。 任选地,生物材料含有添加剂,例如触变剂,不透射线剂或生物活性剂。 在优选实施例中,生物材料用于增加脊柱的至少一个椎骨(椎体成形术)。